www.oncology-central.com

• name: viewport content: width=device-width, initial-scale=1, maximum-scale=2 user-scalable=yes
• name: robots content: index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1
• name: description content: At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.
• property: og:locale content: en_GB
• property: og:type content: website
• property: og:title content: Home
• property: og:description content: At Oncology Central we are dedicated to advancing oncology by publishing trusted, engaging and insightful resources for the global oncology community.
• property: og:url content: https://www.oncology-central.com/
• property: og:site_name content: Oncology Central
• property: article:modified_time content: 2026-05-06T13:23:47+00:00
• name: twitter:card content: summary_large_image
• name: generator content: WordPress 6.7.5

• Skip to main content
• http://www.oncology-central.com/javascript:void(0);
• Oncology Central
• News
• EVENTS COVERAGE
• Opinion
• JOURNAL ARTICLES
• Events calendar
• Spotlights
• In Focus
• https://www.oncology-central.com/feed/
• Journals
• BIOMARKERS
• Diagnostics
• EPIDEMIOLOGY
• Genetics & genomics
• Prevention & screening
• Cancer biology
• CLINICAL TRIALS
• Drug approvals
• Drug development
• EMERGING TECHNOLOGIES
• Industry & business
• Preclinical research
• Chemotherapy
• Immuno-oncology
• Personalized & precision medicine
• Radiology
• Surgery
• Targeted therapies
• Palliative care
• Patient perspectives
• QUALITY OF LIFE AND OUTCOMES
• Survivorship
• Virtual healthcare
• BREAST
• Colorectal
• Endocrine
• Gastrointestinal
• Genitourinary
• Gynecologic
• Head & neck
• Hematologic
• HEPATIC
• LUNG
• Neurologic
• Pancreatic
• Prostate
• Rare tumors
• Renal
• Skin
• Videos
• Podcasts
• Infographics
• Webinars
• Downloadable eBooks
• Register
• The emotional and psychological impact of hepatocellular carcinoma on patients, families and caregivers
• The clinical utility of molecular residual disease testing in early-stage breast cancer
• Is accelerated biological ageing behind the rise in early-onset cancers?
• EHA 2026: Early intervention with teclistamab achieves deep remissions for high-risk smoldering multiple myeloma
• Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study
• Nanowire device captures ovarian cancer biomarkers from blood serum
• First patient receives TCR-T cell therapy targeting mutant
• The promise and challenges of antibody drug conjugates for lung cancer
• The ABC Global Alliance Decade Report: Progress amid growing inequities
• Our Journals
• Journal Content
• Trial watch – antibody-drug conjugates in cancer therapy
• Trial Watch – bispecific T cell engagers and higher-order multispecific immunotherapeutics
• NKT cells: a generalist in disease treatment and a new key to...
• Plain language summary of the management of certain side effects of teclistamab...
• Number needed to treat to avoid progression and death and cost analysis:...
• Managing side effects of talquetamab for relapsed/ refractory multiple myeloma: a plain...
• The prognostic significance of lymph node metastases characteristics in papillary thyroid carcinoma:...
• A plain language summary of the CEPHEUS study: D-VRd for newly diagnosed...
• PYNNACLE Phase II clinical trial protocol: rezatapopt monotherapy for advanced or metastatic...
• Improving access to ABC medicines in high-income countries: the perspective and role of patient advocates, clinicians and pharma
• How is real-world evidence shaping breast cancer care?
• Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study
• CPD study course: Managing menopause after breast cancers
• Infographic: 100 years of groundbreaking Black life scientists
• AWARENESS
• Tackling the rise in early onset cancer: From research to health equity
• Beyond remission: understanding breast cancer dormancy eBook
• The latest advancements in breast cancer survivorship
• Cardiac remodeling linked to higher risks of breast and colorectal cancers
• Unnecessary lymphadenectomy following breast cancer surgery could become a thing of the past
• How are antibody drug conjugates impacting treatment options for breast cancer?
• ASCO 2026: Sacituzumab govitecan combination improves progression-free survival 2 in mTNBC
• ASCO 2026: Skipping axillary lymph node dissection safe for some breast cancer patients
• How is real-world evidence shaping breast cancer care?
• Call for papers: Breast cancer biomarkers in diagnostic and translational pathology -
• ESMO Breast Cancer Congress 2026: Editor highlights
• Could GLP-1 receptor agonists improve breast cancer outcomes for patients with obesity or type 2 diabetes?
• A video summary of the DeLLphi-301 study: tarlatamab as a treatment option for small cell lung cancer
• FOR CLINICIANS
• Local therapy for metastatic NSCLC: in conversation with Fiona McDonald
• Recent advancements in treating
• A video summary of the TOPAZ-1 study PLSP: durvalumab and chemotherapy for advanced biliary tract cancer
• Real-world breast cancer management: insights from Alistair Ring
• A PLSP video summary of the HIMALAYA study: comparing immunotherapy options for unresectable hepatocellular carcinoma
• ASCO 2026: Multi-selective RAS(ON) inhibitor yields unprecedented survival gains for metastatic pancreatic cancer
• ASCO 2026: frontMIND trial – improved progression free survival outcomes for aggressive B-cell lymphoma
• ASCO 2026: Triple therapy outperforms standard treatment in EMERALD-3 hepatocellular carcinoma trial
• KEYNOTE-942 study: Pembrolizumab-vaccine combination cuts melanoma recurrence by 49%
• About
• Accessibility
• Advertising & Sponsorship
• Contact Us
• Editorial Policies
• Expert Panel
• Permissions and content ownership policy
• Contact Us

• Taylor & Francis Group
• About us
• Our journals
• Our Digital Hubs
• https://www.facebook.com/oncologycentral
• https://twitter.com/OncologyCentral
• https://www.linkedin.com/company/oncology-central
• https://www.instagram.com/oncologycentral_/
• https://info.oncology-central.com/follow-us-on-wechat-taylorandfrancis
• https://associationofbreastsurgery.org.uk/
• https://menopauseandcancer.org/
• https://aosw.org/
• https://www.dovepress.com/breast-cancer---targets-and-therapy-journal
• https://www.tandfonline.com/journals/iery20
• https://www.tandfonline.com/journals/ifon20
• Press release policy
• Whitelist emails
• Cookie Policy
• Privacy Policy
• Terms & Conditions

            Domain Name: ONCOLOGY-CENTRAL.COM
Registrar: SafeNames Ltd.
Domain Status: client delete prohibited
Domain Status: client transfer prohibited
Domain Status: client update prohibited
Creation Date: 2010-09-14T16:25:05Z
Registry Expiry Date: 2026-09-14T16:25:05Z
Updated Date: 2025-09-14T23:54:37Z
Name Server: JASON.NS.CLOUDFLARE.COM
Name Server: TIA.NS.CLOUDFLARE.COM
REGISTRAR Contact: SafeNames Ltd.
>>> Last update of RDAP database: 2026-06-02T02:32:33Z         

			User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
Disallow: /wp-content/plugins/
Allow:	/wp-content/uploads/
Disallow: /readme.html
Disallow: /refer/
Disallow: /tag/
Disallow: /author/
Disallow: /wp-login.php
Disallow: /search/
Disallow: *?s=*
Disallow: *?p=*
Disallow: *&p=*
Disallow: *&preview=*
Disallow: /404-error/        

Тецхницал СЕО

СЕО на страници

Садржај и кориснички доживљај